布瑞那韋
臨床資料 | |
---|---|
ATC碼 |
|
識別資訊 | |
| |
CAS號 | 313682-08-5 |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化學資訊 | |
化學式 | C33H41N3O10S2 |
摩爾質量 | 703.82 g·mol−1 |
3D模型(JSmol) | |
| |
|
布瑞那韋(INN:Brecanavir;開發代號:GW640385),或譯作貝卡那韋、瑞卡那韋,是一種蛋白酶抑制劑,已被研究用於治療愛滋病毒。[1]
2006年12月,其開發商葛蘭素史克因配方方面存在難以克服的問題而停止了進一步的開發。[2]
參見
參考資料
- ^ Hazen R, Harvey R, Ferris R, et al. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrob. Agents Chemother. September 2007, 51 (9): 3147–54. PMC 2043237 . PMID 17620375. doi:10.1128/AAC.00401-07.
- ^ GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385) (新聞稿). GlaxoSmithKline. 2006-12-18 [2008-06-11]. (原始內容存檔於2008-12-03).